CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    32,000

CSL Ltd News & Analysis

personal-finance

AFIC bosses on its record discount, passive investing and pricey stocks

A triple headwind has seen Australia's biggest LIC swing to a 10% discount and scuppered its relative performance. Management was bullish in an interview with Firstlinks, but is the discount ever likely to close?
personal-finance

Chart of the week: Blue chips look expensive, more opportunities in smaller caps

This week's chart comes from the Australian equity market outlook for Q4.
personal-finance

12 picks for an income portfolio

An update on how the picks have performed. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,427.60110.901.33%
CAC 407,274.4819.89-0.27%
DAX 4019,884.7585.11-0.43%
Dow JONES (US)42,840.26498.021.18%
FTSE 1008,084.6120.71-0.26%
HKSE19,857.98137.280.70%
NASDAQ19,572.60199.831.03%
Nikkei 22539,052.10350.200.90%
NZX 50 Index12,988.0383.920.65%
S&P 5005,930.8563.771.09%
S&P/ASX 2008,176.90109.901.36%
SSE Composite Index3,374.996.920.21%

Market Movers